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 Adiponectin is a hormone secreted from adipocytes that plays an important role in 
insulin sensitivity and fatty acid oxidation. The secretion of adiponectin from adipose 
tissue has been shown to be attenuated by treatment with prolactin (PRL). PRL is a potent 
STAT5 activator, and studies have indicated that it can modulate the expression of 
several genes in adipocytes. In this study, we demonstrate that 3T3-L1 adipocytes treated 
with PRL exhibit a reduction in adiponectin levels. Furthermore, we identified three 
putative STAT5 binding sites in the mouse adiponectin promoter and show that only one 
of these, located at -3809, binds nuclear protein in a PRL dependent manner. Mutation of 
the STAT5 binding site abrogated PRL dependent protein binding, and supershift 
analysis revealed that STAT5A and 5B, but not STATs 1 and 3, bind to this site in 
response to PRL. Promoter/reporter constructs containing the -3809 site were found to be 
responsive to PRL. Taken together, these data strongly suggest that PRL regulates 











CHAPTER 1. INTRODUCTION 
1.1 Metabolic Syndrome and the Study of Adipocytes 
 The study of adipocytes is important because of the growing epidemic of obesity 
in the United States and the world. Obesity is one of a number of interrelated symptoms 
including, insulin resistance, hypertension, dyslipidemia, and glucose intolerance that are 
collectively referred to as metabolic syndrome (1). Individuals with metabolic syndrome 
have an increased risk of developing atherosclerotic cardiovascular disease as well as 
type II diabetes, and the primary metabolic defects responsible for obesity have been 
found to exacerbate all aspects of metabolic syndrome (1). Some studies have projected 
that 50% of the population in the United States will become obese by the year 2025 (2), 
therefore it is critical to understand the molecular mechanisms that contribute to the 
pathogenesis of obesity and metabolic syndrome.  
 Obesity is a condition in which excess adipose tissue accumulates, so it is logical 
to investigate the primary cell type in adipose tissue, the adipocyte. Mature adipocytes 
possess three properties that largely distinguish them from other cell types. Firstly, 
adipocytes are unique in their ability to store large amounts of lipid in the form of 
triglyceride. Secondly, adipocytes are highly insulin sensitive, which is due largely to 
their expression of the protein glucose transporter 4 (GLUT4). GLUT4 is an insulin 
sensitive glucose transporter that is found exclusively in heart, skeletal muscle, and 
adipocytes. Lastly, studies within the last fifteen years have revealed that adipocytes have 
important endocrine functions. Indeed, several hormones are made exclusively in 
adipocytes and referred to as adipokines. Adipokines have been shown to play critical 
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roles in the metabolic homeostasis of the body, and obese individuals have been reported 
to have an altered circulating adipokine profile that contributes to the etiology of 
metabolic syndrome (3). The goal of this thesis is to elucidate whether the transcription 
of adiponectin, an adipokine hypothesized to have protective effects against metabolic 
syndrome, is regulated by the latent transcription factor Signal Transducer and Activator 
of Transcription 5 (STAT5). 
1.2 Adipocyte Cell Lines as a Model System  
 A lot of what is known about adipocyte biology today has been obtained from 
studies on adipocyte cell lines. Several commonly used adipocyte cell lines were cloned 
from the mouse embryonic fibroblast cell line 3T3 by Green and colleagues back in the 
1970s. Green observed that out of 20 clones taken from the 3T3 stock, 19 of them 
accumulated lipid to various degrees once confluence was reached (4). Only portions of 
these confluent cell populations accumulated lipid and subpopulations prone to lipid 
accumulation were selected and propagated giving rise to the 3T3-L1 and 3T3-F442A 
cell lines used extensively in studies on adipocyte biology (5). The differentiation process 
of these cell lines is thought to be similar to native adipocyte formation from 
preadipocytes, and researchers have found ways to increase the rate of differentiation in 
these cell lines by treating them with hormone cocktails containing: insulin, isobutyl-
methylxanthine (a phosphodiesterase inhibitor), dexamethasone (a synthetic 
glucocorticoid), and fetal bovine serum. Upon differentiation, both cell lines possess the 
major characteristics of native adipoctyes, and experiments have shown that injection of 
3T3-F442A cells into athymic mice form fully developed fat pads, which substantiates 
these cell lines as good model systems (6). 
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1.3 JAK/STAT Signaling  
 Adipocytes possess a number of different signaling pathways, including the Janus 
Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) pathway. In this 
pathway, cytokines bind to a non-enzymatic receptor associated with JAK that dimerizes 
allowing JAK to transphosphorylate the opposite receptor. STAT proteins then bind to 
the phosphorylated receptor, and they themselves are then phosphorylated by the receptor 
associated JAK. Tyrosine phosphorylation of the STAT proteins allows them to dimerize, 
dissociate, and translocate to the nucleus to modulate gene expression (reviewed in 10).  
 There are seven STAT proteins, but only five of these, STATs 1, 3, 5A, 5B, and 6 
are expressed in mature adipocytes (7). The cytokine prolactin (PRL) strongly activates 
STAT5 and to a lesser extent STATs 1 and 3 (8). PRL signaling follows the canonical 
JAK/STAT pathway, but more specifically, when PRL binds the PRL receptor, the 
receptor recruits JAK2 to phosphorylate the receptor and STAT5. It is largely unknown 
what proteins are responsible for mediating the translocation of STAT5 through the 
nuclear pore complex (NPC), but mutational analysis of asparagine 104 on STAT5 has 
shown that this amino acid is essential for IL-3 dependent nuclear import of STAT5 and 
suggests a required protein:protein interaction for STAT5 translocation (9).  
1.4 STAT 5A and 5B  
 STAT5 represents two proteins, 5A and 5B, which are encoded for by separate 
genes on chromosome 11 in mice and are expressed in all tissues at varying levels (10). 
STAT5A and 5B are capable of forming both homo and heterodimers upon activation, 
but the significance of this observation remains unclear in the context of gene regulation 
(11). Both share 96% sequence similarity, and like all STAT proteins, possess a number 
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of domains including: (in order from N-terminus to C-terminus) an N-terminal domain, 
coiled-coil domain, DNA binding domain, Src Homology (SH) 3 domain, SH2 domain, 
tyrosine activation domain, and transcriptional activation domain (TAD). Beginning at 
the amino terminus, the amino terminal domain forms a ring structure consisting of 5 
helices (12). This region has been reported to play an important role in STAT5 dimer and 
tetramer formation, and mutation of tryptophan 37 within this region has been shown to 
ablate tetramer formation (13). The coiled-coil domain consists of a flexible region of 4 α 
helices that protrude from the core structure and serves as a docking site for proteins on 
STAT proteins including N-Myc interactor (Nmi) on STAT 5B (14). The DNA binding 
domain has been documented to bind DNA using a β barrel motif similar to those used by 
the transcription factors p53 and NF-kB (14). Furthermore, X-ray crystallography studies 
of STAT5A have revealed that the β barrel motif has a modest number of contact points 
with bound DNA giving it a dissociation constant in the nanomolar range (15). Next, the 
SH3 domain is thought to facilitate protein:protein interactions between STAT proteins, 
although extensive interactions are known to occur among the other domains (16). An 
SH2 domain lies next to the SH3 domain, and domain swapping studies have suggested 
that the SH2 domain of each STAT family member is the sole determinant in which 
STAT proteins are recruited to activated receptors (17). Additionally, the SH2 domain is 
believed to facilitate the dimerization of STAT proteins by binding to the phosporylated 
tyrosine residue on the oppositely bound STAT (18). Furthermore, like other STAT 
members, STAT5 proteins contain a highly conserved tyrosine residue (Tyr694 on 5A, 
Tyr699 on 5B) that is required for activation. An additional TAD domain is present at the 
carboxyl terminus. STAT5A and 5B differ greatly in both the sequence and size of this 
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domain, and studies have suggested that serine phosphorylation within this region may be 
required for maximal activation of STAT5 proteins (19).  
 Knockout experiments of STAT5A and 5B have revealed both redundant and 
non-redundant functions for these proteins. STAT5A knockouts exhibited defects in 
mammary gland development and were infertile (20). The 5A knockout phenotype was 
strikingly similar to prolactin receptor knockout mice, which suggests that prolactin 
signals primarily through STAT5A (21). Likewise, male STAT5B knockout mice 
exhibited a dwarf phenotype that was similar to growth hormone (GH) receptor knockout 
mice, which suggests that GH signals primarily through STAT5B. STAT5B knockouts 
were, however, sexually dimorphic because female mice did not exhibit stunted growth 
(22). STAT5A/5B double knockouts exhibited severe dwarfism in both sexes, were 
infertile, lacked proper mammary gland development, and had fat pads one-fifth the size 
of wild type mice. These mice also had immune system defects including a lack of 
natural killer cells, and numerous T cell and B cell abnormalities (23).  
1.5 Prolactin and Growth Hormone  
 PRL is produced in the lactotroph cells of the anterior pituitary, as well as other 
locations in the body (24;25). As its name implies, PRL plays a large role in the 
production of milk in pregnant women, but other roles including modulating lipolysis 
(26) and adipogenesis (27) have been identified. Interestingly, except in the case of 
pregnancy, PRL levels in men and women are very similar and it has recently been 
discovered that PRL is produced by adipose tissue in humans (28). As is the case with 
other PRL production sites outside of the anterior pituitary, the PRL gene in adipose 
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tissue is differentially regulated and under the control of a super distal promoter located -
6kb away from the transcription start site (29;30).  
 GH is another known activator of STAT5, and is produced in the somatotroph 
cells of the anterior pituitary gland. It is known that GH increases lipolysis and protein 
synthesis, and decreases lipogenesis and glucose uptake (31). It is also known that 
chronic exposure to GH results in reduced adipose tissue growth (32). Furthermore, 
circulating GH levels are reduced during the condition of obesity (33). Overall, there are 
numerous studies showing that GH is a prominent regulator of adipocyte metabolism 
(34). 
 Both GH and PRL activate the phosphatidylinositol (PI) 3 kinase pathway as well 
as the JAK/STAT pathway. Similarly, insulin utilizes the PI 3 kinase pathway, and 
studies have shown that the effects of insulin on glucose transport, gluconeogenesis, and 
lipogenesis are almost completely dependent on the actions of PI 3 kinase (35). 
Numerous studies have indicated that chronically high levels of GH and PRL can cause 
insulin resistance (36;37) , and it has been hypothesized that these actions involve the 
modulation of PI 3 kinase activity. PI 3 kinase is activated via its recruitment to the 
plasma membrane by Insulin Receptor Substrate (IRS) proteins which, in turn, are 
activated by the insulin, PRL, and GH receptors, respectively. The structure of PI 3 
kinase consists of a heterodimer containing a regulatory p85 subunit and a catalytic p110 
subunit, each of which possess multiple isoforms (35). Knockout experiments of the p85α 
isoform in mice exhibit a phenotype of increased insulin sensitivity (38). In addition, 
other experiments have shown that the overexpression of p85α in cells results in 
decreased glucose uptake and inhibited PI 3 kinase activity (39). Chronically high levels 
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of GH have been shown to induce the transcription of the p85α subunit (40), which may 
account for the concomitant loss of insulin sensitivity seen with this condition.  
1.6 Regulation of the JAK/STAT Pathway 
 JAK/STAT signaling is regulated by a number of different protein interactions. 
Dephosphorylation of activated signaling components by phosphatases such as SH2 
protein tyrosine phosphatase 1 (SHP1) is one method cells use to regulate the JAK/STAT 
pathway. SHP1 consists of two tandem SH2 domains as well as a phosphatase domain 
which has been reported to bind to activated JAK2 (41). Another method of JAK/STAT 
regulation comes from the activation of Suppressors Of Cytokine Signaling (SOCS) 
proteins. The SOCS family consists of 8 members, SOCS 1-7 and Cytokine Inducible 
SH2-containing (CIS) (42). SOCS 1-3 and CIS are activated by PRL (43). Upon 
activation, SOCS proteins bind to an activated receptor or JAK and inhibit their 
interaction with downstream signaling components. Additionally, SOCS proteins contain 
a SOCS box motif that is known to recruit elongin B and C, two proteins involved in the 
ubiquitination and subsequent proteasomal degradation of bound proteins. Contrary to 
SOCS proteins, which are primarily activated by cytokines, Protein Inhibitors of 
Activated STAT (PIAS) proteins are a constitutively expressed class of STAT inhibitors 
found in a number of cell types. One PIAS protein, PIAS3, has been shown to inhibit 
STAT5 signaling by binding and interfering with its ability to bind DNA (44).  
Furthermore, PIAS proteins have been reported to function as Small Ubiquitin like 
modifier (SUMO) E3 ligases (45). The functional consequence of SUMOylation can vary 
depending on the targeted protein, but in the case of STATs, it is hypothesized to 
modulate their activity (46). 
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1.7 Genes Regulated by STAT5 in Adipocytes 
 STAT5 has been reported to play a role in the regulation of a number of genes in 
adipocytes. A previous study has shown that STAT5 plays a role in lipid accumulation in 
mature adipocytes and showed that STAT5 activation represses the induction of fatty acid 
synthase (FAS) (47). Furthermore, another study has shown that STAT5 binds to the 
Acyl CoA oxidase (AOX) promoter and that treatment with STAT5 activators causes an 
increase in AOX mRNA (48). STAT5 has also been reported to play a role in insulin 
resistance and can induce the expression of pyruvate dehydrogenase kinase 4 (PDK4)  in 
adipocytes (49). PDK4 is a kinase that is known to phosphorylate and inactivate the 
pyruvate dehydrogenase complex (PDC), the protein responsible for converting pyruvate 
into acetyl CoA in mitochondria. Hence, when PDC becomes inactive, glucose levels rise 
within the cell which leads to hyperglycemia. This observation correlates well with a 
study that showed that PDK4 activity and expression increases in type II diabetics (50). 
STAT5 has also been reported to play an important role in the activation of genes 
encoding milk proteins. In fact, STAT5 was initially named mammary gland factor 
(MGF), because it was first discovered as an activator of the milk protein β casein (51).  
1.8 Protein Interactions with STAT5 
 A number of studies have shown that proteins that interact with STAT5 can have 
a modulatory effect on its function. The transcription factor CCAAT Enhancer Binding 
Protein (C/EBPβ) has been found to associate with STAT5 in the presence of the 
glucocorticoid receptor (GR), which together form a complex that induces the 
transcription of the β casein gene (52). Additionally, STAT5 has been found to relieve 
repression of the β casein gene by interacting with Yin-Yang factor 1 (YY1), a protein 
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that binds next to the STAT5 response element on the β casein promoter and inhibits β 
casein transcription in the absence of STAT5 (53). Similarly, STAT5 has been reported 
to form an enhancer complex with an adjacent binding transcription factor, Sp1, in the 
promoter region of cyclin D2 (54). Moreover, studies have shown that STAT5 interacts 
with the histone acetylase Creb Binding Protein (CBP)/P300 which serves as a 
coactivator of the β casein gene (55). This interaction is enhanced by the protein Nmi, 
which binds not only STAT5 but other members of the STAT family as well (56). 
1.9 Adiponectin  
 Adiponectin is an adipokine that has recently come into the spotlight as a major 
player in the control of energy homeostasis. The adiponectin gene encodes a protein that 
circulates in serum as high and low molecular weight oligomers (57). A proteolytic 
cleavage product known as globular adiponectin has also been reported (58). Low 
circulating levels of adiponectin have been associated with an increased risk of 
cardiovascular disease (CVD) (59). Men have a higher incidence of CVD than women 
(60), and studies have shown that adiponectin levels on average are lower in men than in 
women (61) which suggests a possible link between low adiponectin levels and the 
development of CVD. Low adiponectin levels have also been observed in obese patients 
(62), and mice lacking adiponectin experience severe hepatic insulin resistance (63). 
Hence, administration of adiponectin to obese animal models with type II diabetes has 
shown that adiponectin can help alleviate insulin resistance in these models (64). 
Moreover, a higher ratio of high molecular weight oligomer/total adiponectin levels has 
been correlated with higher insulin sensitivity, and appears to be more important than 
total adiponectin levels in regards to insulin sensitivity (65). Adiponectin is also known to 
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activate AMP activated kinase whose activity involves increasing fatty acid oxidation and 
increasing glucose transport (66). A recent study also revealed that adiponectin appears to 
play a role in signaling the allocation of triglyceride to white adipose tissue, away from 
other storage sites such as the liver and muscle which are considered to be metabolically 
unhealthy “spill over” sites for fat storage when white adipose tissue becomes unable to 
store excess triglyceride (67).  
1.10 Adiponectin Receptors 
 Two receptors for adiponectin have been identified thus far, AdipoR1 and 
AdipoR2. AdipoR1 is expressed ubiquitously and is most abundant in skeletal muscle, 
whereas AdipoR2 is primarily expressed in the liver (68). Human and mouse adipoR1 
and adipoR2 share 96.8% and 95.2% sequence similarity, respectively (69). The gene for 
AdipoR1 resides on chromosome 1p36.13-q41 in humans and 1E4 in mice and AdipoR2 
is located on chromosome 12p13.31 in humans and 6F1 in mice (70). AdipoR1 and 
AdipoR2 share 66.7% sequence identity and both are predicted to form 7 transmembrane 
domain proteins similar to receptors belonging to the G-protein-coupled receptor (GPCR) 
families. However, GPCR receptors and adiponectin receptors are only distantly related 
because the N-terminus of the adiponectin receptor resides in the cytosol and the C-
terminus resides externally which is opposite to that of typical GPCR receptors. It has 
also been shown that globular adiponectin binds to AdipoR1 with a higher affinity than 
AdipoR2 and that full length adiponectin binds to AdipoR2 more tightly than AdipoR1 
(71). Human studies have revealed that AdipoR1/R2 mRNA is upregulated after exercise 
in human skeletal muscle (72). Furthermore, families with a history of type II diabetes 
have been reported to have lower AdipoR1/R2 expression levels than families without a  
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history of type II diabetes (73). 
1.11 Actions of Adiponectin 
 A number of studies have shown that adiponectin increases insulin sensitivity and 
fatty acid oxidation throughout the body. When adiponectin binds to one of its receptors, 
the protein Adaptor-Protein containing Pleckstrin and phosphotyrosine domains and 
Leucine zipper motif (APPL1) associates with the receptor and becomes activated (74). 
Upon activation, APPL1 has been documented to associate with the monomeric GTPase 
Rab5, which is known to play a major role in endocytosis (75). APPL1 has also been 
reported to activate the protein kinase LKB1, a known tumor suppressor that lies 
upstream of AMP kinase (AMPK). AMPK is a heterotrimeric protein that consists of a 
catalytic α subunit and two regulatory β and γ subunits. AMPK serves as the global 
energy regulator of the cell by detecting the ratio of 5’-AMP/ATP, where 5’-AMP 
activates AMPK and 5’-ATP inhibits AMPK. One mechanism in which AMPK increases 
fatty acid oxidation is by phosphorylating acyl-CoA carboxylase (ACC) (76). 
Phosphorylated ACC results in a reduction of malonyl-CoA production, an inhibitor of 
long chain acyl-CoA carnitine palmitoyltransferase 1 (CPT1). Thus, low levels of 
malonyl-CoA result in increased transport of long chain acyl-CoA into the mitochondrial 
matrix resulting in increased fatty acid oxidation. 
 Adiponectin signaling has been reported to activate p38 Mitogen Activated 
Protein Kinase (MAPK) (77). The MAPK kinases (MAPKK) MEK3 and MEK6 are 
responsible for activating p38 MAPK, however, it is unknown how MEK3 and MEK6 
are activated by adiponectin because they lie downstream from numerous upstream 
MAPKK kinases (MAPKKK) (78). Activated p38 MAPK phosphorylates and activates 
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PPARα, a nuclear receptor that, like PPARγ, forms an obligate heterodimer with the 
retinoid X receptor (RXR). PPARα is responsible for the transcriptional control of 
numerous enzymes responsible for fatty acid oxidation and is activated not only by p38 
MAPK, but ligands such as arachidonic acid derivatives, long chain fatty acids, and 
fibrates (79). Activated PPARα upregulates the expression of Fatty Acid Transport 
Binding Protein (FATP), as well as a host of enzymes involved in β oxidation such as 
medium chain acyl CoA dehydrogenase (MCAD), acyl CoA Oxidase (ACO), and 
cytochrome P450 fatty acid ω-hydroxylase (80).  
 Adiponectin is also responsible for increased insulin sensitivity in numerous cell 
types. A mechanism for this action has been hypothesized by Wang et al. in C2C12 
myotubes that involves prolonging the activation of Insulin Receptor Substrate 1 (IRS-1) 
in response to insulin by inhibiting S6 kinase, an inhibitor of IRS-1 (81). S6 kinase is 
activated by the mammalian Target Of Rapamycin (mTOR)/raptor complex, and 
treatment with rapamycin, an mTOR/raptor inhibitor, decreased the activity of S6 kinase 
on IRS-1. Interestingly, treatment with adiponectin also inhibited S6 kinase activity on 
IRS-1 and further experimentation revealed a likely pathway in which AMPK (activated 
by adiponectin) activates the tuberous sclerosis complex (TSC1/2), which inhibits Ras 
homology enriched in brain (Rheb), an activator of the mTOR complex. Thus, a possible 
pathway for the insulin sensitizing effects of adiponectin has been shown in C2C12 
myotubes.  
1.12 Single Nucleotide Polymorphisms of the Adiponectin Gene                               
 The human adiponectin gene is located on chromosome 3q27, which is a region of 
DNA in which more than a dozen Single Nucleotide Polymorphisms (SNPs) have been 
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linked to type II diabetes and metabolic syndrome (82-84). SNPs within the proximal 
promoter of adiponectin have been identified and it has been observed that  individuals 
with an SNP of G/G at -276 of the transcription start site (the binding site of PPARγ) 
have a two fold higher risk of developing type II diabetes when compared to individuals 
with an SNP of T/T (85). Other more distally located SNPs have been found at -11377 
and -11391 and are associated with hypoadiponectinemia and type II diabetes (86). SNPs 
with metabolic implications within the adiponectin gene itself have also been identified. 
Individuals with SNP 45 on exon 2 independently or combined with the -276 SNP exhibit 
an increased risk of obesity and insulin resistance (87). Moreover, individuals with an 
I164T missense mutation have been observed to have significantly lower levels of 
adiponectin independent of body mass index (BMI) (88). 
1.13 Transcriptional Control of Adiponectin 
 Numerous studies have examined the transcriptional control of the human 
adiponectin gene. Deletion analysis of the human adiponectin promoter region has 
demonstrated that the region from -676 to +41 is sufficient for basal level transcription 
activity (89). Furthermore, mutation analysis of response elements for Sterol Regulatory 
Element Binding Protein (SREBP) -423 and CCAAT/enhancer binding protein (C/EBP) 
at -224 has shown that both sites are necessary for basal level transcription (90). Another 
study has revealed that there are multiple C/EBPα sites within the first intron of the 
human adiponectin gene that serve to enhance basal level transcription (91). The 
adiponectin promoter also contains a Peroxisome Proliferator Activated Receptor γ 
(PPARγ) response element (PPRE) at -273 that allows the nuclear receptor PPARγ to 
activate the adiponectin gene (92). Activation of the adiponectin gene can also be 
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achieved through the use of thiazolidinediones, a class of drugs that serve as artificial 
PPARγ agonists. Moreover, an orphan nuclear receptor known as Liver Receptor 
Homolog-1 (LRH-1) has been reported to bind to -229 of the human adiponectin 
promoter and mutation analysis of this binding site has revealed that it is required for 
both basal and induced transcription (93). 
  The promoter region of adiponectin in mice has also been extensively studied. 
The transcription factor forkhead transcription factor O1 (FOXO1) has been reported to 
bind the mouse promoter at -670 and -610 and serves to upregulate adiponectin. FOXO1 
is a known target of protein kinase B (PKB), a protein kinase activated by insulin and 
various growth factors (94). Phosphorylation of FOXO1 by PKB results in its exclusion 
from the nucleus and renders it incapable of inducing the transcription of adiponectin. 
Moreover, FOXO1 has been found to form a complex with C/EBPα at these sites (95), 
and this interaction is enhanced by the protein deacetylase Silent Information Regulator 2 
Mammalian Ortholog (SIRT1), which deacetylates 3 lysine residues in the forkhead DNA 
binding domain (96). Furthermore, a study in mice has shown that C/EBP and Nuclear 
Factor-Y (NF-Y) bind the -73 to -117 region of the adiponectin promoter and that 
mutation or deletion of this region results in dramatically reduced transcription levels 
(97).  
 Sequence analysis of the human and murine adiponectin promoters reveal a 
number of potential transcription factor binding sites that are unpublished. Similar to the 
human LRH-1 site previously described (74), a potential LRH-1 site is located at -124 of 
the murine adiponectin promoter that resembles an LRH-1 binding site found at -48 and -
55 of the rat Cyp8b1 gene (98) (Table1). Furthermore, the murine adiponectin promoter 
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contains a potential PPARγ response element (PPRE) at -554 similar to those found in 
other genes including the ARE7 site found in the mouse AP2 gene (99) (Table 1). 
Moreover, a possible NF-Y binding site is present at -380 of the human adiponectin 
promoter (Table 1), which is similar to the sites already found in the murine adiponectin 
promoter (78). A comparison of the mouse and human adiponectin promoter regions is 



















Table 1. Comparison of Promoter Response Elements 
 
Gene                                                   LRH-1 Sequence                                     Position 
Human adiponectin                            TCAAGGCCT                                   -229 (ref. 74) 
Rat Cyp8b1                                        GCAAGGTCC                                    -55 (ref. 79)   
Rat Cyp8b1                                        CCAAGGGCA                                    -48 (ref. 79) 
Mouse adiponectin                            GCAAGGGCA                                -124 (putative) 
 
Gene                                                    PPRE Sequence                                     Position 
Human adiponectin                             GGGCA A AAGTCA                        -273 (ref. 74)              
Mouse AP2                                         TGAACT C TGACCC                    ARE7 (ref. 80) 
Mouse adiponectin                             TGAACT C AGGACC                 -554 (putative) 
 
Gene                                                     NF-Y Sequence                                       Position 
Mouse Adiponectin                               ATTGG                                               -73 (ref. 78) 















































































































































































































































































































































































CHAPTER 2. MATERIALS AND METHODS 
 
2.1 Materials 
 STAT5A and adiponectin antibodies were purchased from Santa Cruz 
Biotechnology. [α-32P] dCTP was purchased from Perkin-Elmer and dTTP, dATP, dGTP 
were purchased from Amersham Biosciences. Klenow and Klenow buffer were 
purchased from Promega. Fetal bovine serum (FBS) was purchased from Atlanta 
Biologicals and calf serum was purchased from Biosource. Sheep prolactin was 
purchased from Sigma. Bicinchoninic Acid (BCA) was purchased from Pierce. 
Oligonucleotide probes were ordered from Integrated DNA Technologies.  
2.2 Cell Culture  
 Murine 3T3-L1 preadipocytes were plated and grown to 2 days post-confluence in 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% bovine serum. 
Medium was changed every 48 hours. Preadypocytes were differentiated into adipocytes 
by changing the medium to DMEM containing 10% fetal bovine serum, .5 mM 3-
isobutyl-methylxanthine, 1 uM dexamethasone, and 1.7 uM insulin (MDI). After 48 
hours, medium was replaced with DMEM supplemented with 10% FBS and cells were 
allowed to differentiate for 5 days. After differentiation, medium was changed every 48 
hours and fully differentiated adipocytes were maintained until harvested for 
experimentation. 
2.3 Preparation of Nuclear and Cytosolic Extracts 
 Cell monolayers were rinsed with PBS buffer and nuclear homogenization buffer 
(NHB) was added containing 20 mM Tris (pH 7.4), 10 mM NaCl, 3 mM MgCl2, 1 uM of 
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dithiothreitol, 1 uM phenylmethylsulfonyl fluoride, 1 uM pepstatin, 50 trypsin inhibitory 
milliunits of aprotinin, 10 uM leupeptin, and 2 mM sodium vanadate. Igepal CA-630 
(Nonidet P-40) was added to a concentration .15% before each extraction and 
homogenized 16 times in a Dounce homogenizer. Resulting homogenates were then 
centrifuged at 1500 rpm for 5 minutes at 4°C. Supernatants were decanted and saved as 
cytosolic extracts. The nuclear pellets were then resuspended in ½ the volume of NHB 
used previously and centrifuged as before twice to wash the nuclei. The nuclei pellet was 
then resuspended in extraction buffer containing 20 mM HEPES (pH 7.9), 420 mM NaCl, 
1.5mM MgCl2, .2mM EDTA, 1 uM dithiothreitol, 1 uM phenylmethylsulfonyl fluoride, 1 
uM pepstatin, 50 trypsin inhibitory milliunits of aprotinin, 10 uM leupeptin, 2 mM 
sodium vanadate, and 25% glycerol. Nuclei were then extracted on ice for 30 minutes to 
1 hour with frequent inversion to ensure proper extraction. Afterwards, samples were 
centrifuged at 10,000 rpm at 4°C for 10 minutes to pelletize cell debris. Supernatants 
containing the nuclear extracts were then analyzed for protein content using the BCA 
assay kit, aliquoted, and frozen at -80°C for later use.  
2.4 Preparation of Whole-Cell Extracts 
 Cell monolayers were rinsed with PBS and then harvested in a non-denaturing 
buffer containing 10mM Tris (pH 7.4), 150 mM NaCl, 1mM EGTA, 1mM EDTA, 1% 
Triton X-100, 0.5% Nonidet P-40, and 1 uM phenylmethylsulfonyl fluoride. A protease 
inhibitor cocktail was added to this buffer before each experiment consisting of 1 uM 
phenylmethylsulfonyl fluoride, 1 uM pepstatin, 50 trypsin inhibitory milliunits of 
aprotinin, 10 uM leupeptin, and 2mM sodium vanadate (a phosphatase inhibitor). 
Samples were extracted for 30 minutes on ice and centrifuged at 15,000 rpm at 4°C for 
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15 minutes. Supernatants containing whole cell extracts were analyzed for protein content 
by bicinchoninic acid (BCA) analysis according to the manufacturer’s protocol.  
2.5 Western Blotting 
 Whole cell extracts were run on a 7.5% polyacrylamide gel containing SDS using 
the Laemmli method (100). Proteins were transferred to nitrocellulose (Bio-Rad) in 25 
mM Tris, 192 mM glycine, and 20% methanol under a current of 55 volts for 4 hours at 
4°C. After transfer, nitrocellulose membranes were blocked overnight in TBS buffer 
(.025M Tris, .125M NaCl, .1% Tween 20) containing 4% powdered milk. Nitrocellulose 
membranes were washed twice for 10 minutes on an orbital shaker and exposed to rabbit 
derived primary antibodies specific for adiponectin or STAT5A for 1.5 hours. 
Membranes were then washed for 15 minutes in TBS buffer 3 times and exposed to 
rabbit specific secondary antibodies conjugated to horseradish peroxidase (Jackson 
ImmunoResearch Laboratories) for 1.5 hours. Afterwards, membranes were washed for 
10 minutes in TBS buffer 3 times and visualized using enhanced chemiluminescence 
(Pierce) according to the manufacturer’s protocol.   
2.6 Electrophoretic Mobility Shift Assay (EMSA) 
 Primary and complementary DNA oligonucleotide strands (Table 2) were 
combined (10 ug each strand) and heated for 5 minutes in a 95°C water bath. 
Oligonucleotide strands were allowed to cool and anneal overnight forming double 
stranded oligonucleotide probes. Oligonucleotide probes were radioactively labeled by 
combining 4 ug of DNA probe with Klenow, Klenow buffer, 20 uCi α-32P dCTP, .33 mM 
dATP, dGTP, dTTP, and incubating the reaction for 15 min. at 30°C. The reaction was 
stopped by adding 1 ul of .5M EDTA. Probes were purified from the reaction mixture 
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using micro Bio-Spin 30 chromatography columns (Bio-Rad). Probe purity was measured 
by running samples on TLC plates (Sigma) in a reservoir of .5 M KH2PO4 and exposing 
the plates to autoradiography film. Specific probe activity was measured by scintillation 
and typically measured 50,000 cpm/ul. Samples were prepared using the method 
described by Ritzenthaler (101) and loaded onto a pre-run (200V for 1 hour at 4°C) TBE 
gel consisting of 6% polyacrylamide/bisacrylamide (40:1 polyacrylamide to 
bisacrylamide), 90 mM Tris, 90 mM boric acid, and 2 mM EDTA, pH 8.0. Cold 
competition experiments were performed by serial diluting 2 µl of stock unlabled probe 
two fold for each successive sample and combining 1 µl of diluted probe with 1 µl 
radiolabeled probe before incubation with nuclear extracts. Supershift analysis was 
performed by incubating 1.5 ug/ul of antibody with nuclear extracts for 1 hour at room 
temperature prior to incubation with the DNA probe. 
2.7 Plasmid Construction  
 The region corresponding to the -3809 site and the 125 bp flanking it were 
amplified by PCR. PCR primers were designed using the primer 3 progam which can be 
found at the website http://biotools.umassmed.edu/bioapps/primer3_www.cgi. Restriction 
sites for NheI and HindIII were added to primer ends to facilitate directional cloning 
(Table 3). PCR reaction conditions consisted of 45 µl of platinum PCR supermix HiFi 
(Invitrogen), .5 µl of each primer from a 20 picomolar stock, and 100 ng of genomic 
DNA from 3T3-L1 adipocytes. PCR was performed using an MJ Research PTC-100 
machine set to cycle at 1) 94° for 2 minutes 2) 94° for 30 seconds 3) 55° for 30 seconds 
4) 68° for four and a half minutes, which was then repeated 35 times beginning with step 
2. Amplicons were purified and digested with NheI and HindIII according to the  
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Table 2. Primary and Complementary DNA strands Used in EMSAs 
 
Site                                                                                                   Primary Strand                               
-3196                                                      5’-GGAGTGTTCTCAGAAAATGAAAAAA-3’                               
-3394                                                                       5’-ACTGGCCTTCGGAGAAAAG-3’                               
-3809                                                    5’-GAGGCCCTGAATTCTAATTCCCAGAA-3’           
β-Casein                                                   5’-GCCATGGTTTTCTTGGAACTCACTAT-3’              
Site                                                                                                   Complementary Strand 
-3196                                                                           5’-TTTTTTCATTTTCTGAGAA-3’ 
-3394                                                                           5’-TGACTTGCTTTTCTCCGAA-3’ 
-3809                                                      5’-GTGGTTTCTGGGAATTAGAATTCAGG-3’ 
β-Casein                                                  5’-GAGGCCCTGAATTCTAATTCCCTTAA-3’ 
 
manufacturer’s instructions (New England Biolabs). The pGL4.27 luciferase vector 
(Promega) was also digested with NheI and HindIII and ligated to the previously digested 
amplicons by using T4 DNA ligase according to the manufacturer’s instructions (New 
England Biolabs) giving rise to the PGL4-Adipo construct.  
2.8 Transformation and Plasmid Preparation                                                             
 One Hundred microliters of Dh5α competent cells (Invitrogen) were diluted five 
fold in Tris-HCl (pH 7.5) and 1 mM EDTA. One microliter of DNA (containing 1-10ng 
DNA) was added and cells were incubated on ice for 30 minutes. Cells were then 
transformed by heat shock for 45 seconds in a 42°C water bath and placed on ice for 2 
minutes prior to the addition of .9 ml of room temperature S.O.C. medium. Cells were 
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then shaken at 225 rpm, 37°C for 1 hour and diluted 1:10 with S.O.C. medium. One 
hundred microliters from this suspension was then spread on fresh LB plates containing 
100 µg/ml of ampicillin before being placed in a 37°C incubator overnight. Colonies 
from overnight plates were used to inoculate 20 ml of LB broth containing 100 µg/ml of 
ampicillin and grown for 8 hours. Cells were diluted 1:1000 and grown for 12-16 hours in 
LB broth containing 100 µg/ml of ampicillin. Afterwards, cells were pelleted by 
centrifugation at 6,000 x g for 15 minutes at 4°C. Plasmids were isolated from cell pellets 
using a Qiagen endofree maxi kit according to the manufacturer’s instructions. 
Table 3. PCR Primers Used in This Study 
 
Name                                                        Sequence                                   Restriction Site 
PGL4-Adipo      5’-GATCGCTAGCATGCAGGGCTCTCTGTTTTG-3’             Nhe1 
PGL4-Adipo     5’-GATCAAGCTTGGAGCAACTGGAGCCAACTA-3’            Hind3 
 
2.9 Transfections and Luciferase Assays 
 3T3-L1 adipocytes were differentiated for 6-8 days. Next, differentiation medium 
was removed and cells were washed twice with PBS buffer and trypsinized using 5x 
trypsin (Sigma) for 1 minute. Trypsinization was stopped by re-adding differentiation 
medium supplemented with 4% glycerol and cells were centrifuged at room temperature 
for 5 minutes at 90 g. Next, cells were resuspended in 10 ml of differentiation medium 
supplemented with 4% glycerol and cell density was determined using a hemocytometer. 
An appropriate number of cells (2 x 106 cells per 100 µl) were then centrifuged at room 
termperature for 5 minutes at 90 g. Cells were resuspended to a volume containing 2x106 
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cells per 100 μl in room temperature nucleofector L solution (Amaxa) and 2.5 μg of 
PGL4-Adipo was added, along with 250 ng of CMV/renilla vector to control for 
transfection efficiency. Amaxa cuvettes were loaded with 100 μl of cell suspension and 
transfection was performed using program A-033 on an Amaxa Nucleofector II device. 
After transfection, 500 µl of pre-warmed differentiation medium was added to the cells in 
the cuvette and cells were transferred to one well in a 6 well plate containing 2 ml of pre-
warmed differentiation medium. Re-plated cells were allowed to grow for 2 hours until 
medium was changed to DMEM containing 1% calf serum. Upon changing the medium, 
cells were treated with 450 nM PRL or left untreated and grown for 48 hours. Cells 
previously treated with PRL were treated again after 24 hours and after 48 hours cells 
were aspirated and washed twice with PBS buffer before being lysed with 500 µl of 
passive lysis buffer (Promega). PGL-4 Adipo activity was quantified by adding 20 μl of 
cell lysate to 100 µl of LARII reagent (Promega) and mixed by pipetting 2-3 times before 
being placed in a Berthold Detection Systems Sirius luminometer set to automatically 
read after closing the sample door with a 2 second pre-measurement delay followed by a 
10 second measurement interval. Immediately following luciferase detection, co-
transfected CMV/renilla vector was measured by adding100 μl of Stop and Glo reagent 
(Promega) and samples were briefly vortexed before being placed back in the 
luminometer for detection. Relative light units (RLU) were calculated by dividing firefly 





CHAPTER 3. RESULTS 
3.1 Prolactin Treatment Results in a Time Dependent Decrease in Adiponectin 
Expression in 3T3-L1 Adipocytes 
 
 Previous studies have shown that PRL can cause a decrease in adiponectin 
expression in human adipose tissue explants as well as mice (102). PRL is a potent 
STAT5 activator, therefore we hypothesized that STAT5 may play a role in the hormonal 
induced down regulation of adiponectin expression. To determine if fully differentiated 
3T3-L1 adipocytes were chronically treated every 24 hours with 1 nM PRL for 96 hours. 
Cells were harvested at various time points and western blot analysis was performed on 
whole cell extracts (Fig. 2). These studies revealed that adiponectin levels were 
 
0 12 24 48 72 Hours Prolactin
 
Fig. 2. PRL treatment decreases the expression of adiponectin in 3T3-L1 adipocytes. 
Fully differentiated 3T3-L1 adipocytes were maintained in DMEM containing 10% FBS 
and treated with 1 nM PRL every 24 hours until harvested at the times indicated. Forty 
micrograms of whole cell extract were subjected to SDS-PAGE and transferred to 
nitrocellulose for western blot analysis. STAT5A levels are shown as a loading control. 
This is a representative experiment independently performed 2 times.  
 
decreased within 48 hours and remain lowered for the duration of PRL treatment. 
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3.2 Prolactin Treatment Induces STAT5 Binding of the Murine Adiponectin 
Promoter in vitro  
 
 To determine if the down regulation of adiponectin was due to transcriptional  
repression by PRL activated STAT5, we analyzed the first 4,000 bp of the adiponectin 
promoter for consensus STAT5 binding sites (TTC NNN GAA). Three consensus STAT5 
binding sites were identified at -3196, -3394, and -3809 bp from the transcription start 
site (Table 4). To evaluate if these sites bound protein in response to PRL, EMSA 
analysis was performed using nuclear extracts obtained from serum deprived cells treated 
with 20 nM PRL for 15 minutes. As seen in figure 3, the site at -3809 binds to PRL 
induced nuclear protein complexes, where as the sites at -3196 and -3394 sites do not 
bind protein in response to PRL. The well characterized prolactin responsive STAT5  
Table 4. PRL Responsive Sequences 
 
Position                                      Sequences                                               PRL-Responsive 
-3196                                       TTC TCA GAA                                                   No 
-3394                                      TTC GGA GAA                                                   No 
-3809                                      TTC TGG GAA                                                   Yes 
-3809 Mutant                          TTA AGG GAA                                                   No 
β-Casein                                 TTC TAG GAA                                                   Yes 
 
binding site at -119 of the β casein promoter was analyzed as a positive control (Fig. 3, 
lane 8). Nuclear extracts obtained from untreated cells were used as a negative control 









‐3196  ‐3394 ‐3809 ‐119
Lane      1       2         3     4       5      6       7       8       9 
Fig. 3. PRL stimulates protein binding to the -3809 site in the mouse adiponectin 
promoter. Nuclear extracts were prepared from serum deprived 3T3-L1 adipocytes 
untreated or treated with 20 nM PRL for 15 minutes. Radiolabled probes corresponding 
to potential STAT5 binding sites with an activity of 50,000 cpm/ml were incubated with 
10 µg nuclear extracts and subjected to EMSA analysis to analyze for binding activity. A 
probe corresponding to a known STAT5 binding site in β casein promoter is included as a  











-3809 site, EMSA analysis was performed using probes with a mutated STAT5 binding 
site (Table 4). Mutation of the consensus STAT5 binding site resulted in the ablation of 
PRL responsive protein binding to the -3809 site (Fig. 4). Additionally, cold competition 
experiments were performed and showed that increasing concentrations of unlabeled        
-3809 probe were able to compete for PRL dependent protein binding (Fig. 5), and that 
unlabeled β casein probe was also able to compete for protein binding (Fig. 5, lane 9). 
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Fig. 4. Mutation of the consensus STAT5 binding sequence ablates PRL induced 
protein binding to the -3809 site. Wildtype and mutant probes (Table 3) were incubated 
with 10 µg PRL treated nuclear extracts and subjected to EMSA analysis. This is a 
representative experiment individually performed two times. 
 
 To determine if PRL activated STAT proteins bound to the -3809 site, we 
performed supershift analysis using antibodies specific for STAT proteins known to be 
activated by PRL. As shown in figure 6, an antibody for STAT5A partially shifted the 
PRL induced complex more than the antibody for STAT5B. This may be due to PRL 
preferentially activating STAT5A more than STAT5B (11). Nonetheless, these shifts 
indicate that both STAT5A and STAT5B bind the -3809 site in response to PRL in vitro. 
Furthermore, antibodies specific for STATs 1 and 3 were unable to shift the PRL 
activated complex, which indicates that these proteins do not bind to the -3809 site in 
response to PRL treatment.
PRL + +- 
MWT
Lane    1       2        3
 
 




Lane    1      2       3       4      5      6      7      8       9 
Fig. 5. Cold competition analysis reveals that unlabeled probe can compete for PRL 
activated protein-DNA complexes. 32P radiolabeled probe with an activity of 50,000 
cpm/ml was serial diluted with 50 nM to 5 µM of unlabeled probe and combined with 10 
µg of PRL treated nuclear extracts. Five micromoles of unlabeled β casein probe was 
used in lane 9. Complexes were resolved by EMSA. This is a representative experiment 
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Free probe + - + + + + PRL 
STAT1 STAT3 STAT5A STAT5B - - 
Lane       1             2             3             4            5             6             7 
Fig. 6. PRL induces STAT5A and STAT5B binding to the -3809 site in the mouse 
adiponectin promoter. Ten micrograms of PRL treated nuclear extract was incubated 
with 1.5 ug antibody specific for indicated STAT proteins for 1 hour at room temperature 
prior to incubation with 50,000 cpm/ml of radiolabeled -3809 probe. Complexes were 
















3.3 Luciferase Assay 
 In order to determine if the adiponectin promoter was responsive to PRL 
treatment in living cells, fully differentiated 3T3-L1 adipocytes were transiently 
transfected with the PGL4-Adipo vector containing the -3809 site and the 125 bp 
surrounding it. Cells were left untreated or treated with 450 nM of PRL for 48 hours and 
luciferase activity was measured using a Berthold Detection Systems Sirius luminometer. 
PRL treated cells exhibited an increase in luciferase activity compared to cells left 
untreated (Fig 7). Thus, stimulation with 450 nM of PRL appears to cause an increase in 
PGL4-Adipo activity. 
Expression of the PGL4-Adipo Promoter/Reporter Construct 















Fig. 7. Treatment with PRL modulates adiponectin promoter/reporter construct 
activity in 3T3-L1 adipocytes. Fully differentiated adipocytes were transiently 
transfected with the PGL-4 Adipo vector containing the -3809 site and the 125 bp 
flanking it. PRL treated cells were stimulated with 450 nM of PRL for 48 hours and a 
CMV/renilla vector was co-transfected to account for transfection efficiency. Relative 
light units (RLU) were calculated by dividing firefly luciferase activity by renilla 
luciferase activity. Results were done in triplicate. This is a representative experiment 
independently performed 3 times. 
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CHAPTER 4. DISCUSSION 
4.1 Summary 
 Adiponectin levels in 3T3-L1 adipocyte whole cell extracts were shown to 
decrease over time in response to chronic PRL treatment. PRL is a potent STAT5 
activator, therefore the mouse adiponectin promoter was scanned for potential STAT5 
binding sites. After scanning, three classical STAT5 binding sites were found and EMSA 
analysis revealed that one site, at -3809, bound protein complexes in response to PRL. 
Four independent pieces of data showed that STAT5 specifically bound to the -3809 site. 
First, cold competition experiments showed that the prolactin induced protein complex 
could be specifically competed for by unlabeled oligonucleotide probe corresponding to 
the -3809 site. Secondly, unlabeled oligonucleotide probe corresponding to the well 
characterized STAT5 binding site in the β casein promoter was also able to compete for 
PRL induced complex binding. Moreover, EMSA supershift analysis showed that both 
STATs 5A and 5B specifically bound to this site, where as STATs 1 and 3 did not. 
Lastly, mutation of the STAT5 binding site resulted in the ablation of PRL induced 
protein complex binding which suggests that a classical STAT5 binding site is necessary 
for protein complex formation. 
 Luciferase experiments indicated an elevation in PGL4-Adipo activity upon 
stimulation with PRL. These results may be an artifact of the PGL4-Adipo vector, (which 
uses the -3809 site and the 125 bp surrounding it to drive the expression of the luciferase 
gene) because the full length adiponectin promoter may contain response elements that 
work in cooperation with the STAT5 binding site to silence adiponectin gene 
transcription. Furthermore, dose dependency experiments (data not shown) demonstrated 
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that 450 nM of PRL caused the most potent activation of STAT5, however, lower doses 
of PRL could potentially have a different effect on PGL4-Adipo activity. 
4.2 Possible Mechanisms of Adiponectin Regulation 
 The reduction in adiponectin protein levels is likely due to STAT5 binding to the 
adiponectin promoter, which eventually causes the down regulation of the adiponectin 
gene. Yet, adiponectin protein levels do not decrease until roughly 48 hours after PRL 
treatment. The cause of this delay may be due to the stability of adiponectin mRNA, 
however, since western blot analysis was done using cells maintained in DMEM 
containing 10% FBS, the upregulation of the adiponectin gene by transcription factors 
activated by growth factors in the media cannot be ruled out. Therefore, luciferase assays 
were performed using 1% calf to help minimize the effects that other growth factors may 
have on adiponectin gene expression. 
 Similar studies have been performed on a STAT5 binding site approximately 
4000 bp away from the transcription start site of the Interleukin 2 Receptor α (IL2Rα) 
(103). This site not only contains a consensus STAT5 binding site, but a partial STAT5 
binding site 11 bp away which has been shown to facilitate the tetramerization of STAT5 
proteins (104). In addition, mutation of N-terminal STAT5 residues ablated tetramer 
formation and resulted in the loss of STAT5 activity on the IL2Rα gene. Interestingly, we 
have observed that the site found at -3809 also contains a partial STAT5 binding site 
located 6 bp away (Table 5). Extensive studies have been made showing enhanced 
STAT5 binding activity to tandem STAT5 binding sites (105), and it has been suggested 
that oligomerization of STAT proteins may contribute to DNA binding specificity (106), 
therefore binding to the -3809 site may be due to the presence of a partial STAT5 binding 
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site. Other studies have shown that activation of STAT5 alone cannot modulate the 
expression of the IL2Rα gene (107), and that cooperation with other transcription factors, 
such as Elf-1, are necessary for full activity. Thus, the activity of STAT5 on the 
adiponectin gene likely involves the recruitment of a number of proteins that work in 
cooperation to turn off adiponectin gene transcription.  
Table 5. Human and Murine Adiponectin Promoter STAT5 Binding Sites with 
Surrounding Bases  
 
Sequence                                                             Location from Transcription Start Site 
5’-ggaacttccccacaccccagttctcagaattcatgtgcaaggtctttcc-3’                        - 561 (Human) 
5’-tgccacttcaagcctaaactttctaggaacacctaagtgggtggcagct-3’                       -910 (Human) 
5’-cctactttgtgccaggttctattctaggaactaagggatacaactttgaa-3’                        -1851 (Human) 
5’-cagtggaagtcagtctggagtgttctcagaaaatgaaaaaatagctgggca-3’                  -3196 (Murine) 
5’-caaatgacttatctgatacactggccttcggagaaaagcaagtcaacacctcatt-3’              -3394 (Murine) 
5’-gttgtgagccatcatgtggtttctgggaattagaattcagggcctctgc-3’                        -3809 (Murine) 
 
4.3 Potential Impact of STAT5 Regulation of Adiponectin 
 Prolactin release from the pituitary is pulsatile and occurs approximately every 95 
minutes in men (108). Continuous PRL release is inhibited by dopamine, which signals 
through the D2 receptor (D2R) on the surface of lactotrophs. Studies have shown that 
D2R expression in obese animal models is lowered, and that subsequent activation of the 
D2R in these models results in reduced body mass (109). Interestingly, it has been 
documented that pulsatile prolactin release in obese women is elevated in proportion to 
the amount of visceral fat excess (110), which may be the result of lowered dopaminergic 
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inhibition of PRL release. Furthermore, plasma PRL concentrations are highest during 
sleep (111), and studies have indicated that individuals with increased abdominal 
circumference (an indicator of visceral fat content), experience enhanced insulin 
resistance during sleep (112). Therefore, taking into account the data presented in this 
thesis, it can be hypothesized that elevated PRL levels during the condition of obesity 
causes a decrease in the amount of adiponectin released by adipocytes. As previously 
mentioned (56), lowered levels of adiponectin over time may result in the unnatural 
storage of triglyceride in muscle and liver which is a condition heavily correlated with the 
development of metabolic syndrome. Thus, lowered levels of adiponectin due to the 



























 1.  Moller,DE, Kaufman,KD: Metabolic syndrome: a clinical and molecular 
perspective. Annu Rev Med 56:45-62, 2005 
 2.  Kopelman,PG: Obesity as a medical problem. Nature 404:635-643, 2000 
 3.  Waki,H, Tontonoz,P: Endocrine functions of adipose tissue. Annu Rev Pathol 
2:31-56, 2007 
 4.  Green,H, Kehinde,O: An established preadipose cell line and its 
differentiation in culture. II. Factors affecting the adipose conversion. Cell 
5:19-27, 1975 
 5.  Green,H, Kehinde,O: Spontaneous heritable changes leading to increased 
adipose conversion in 3T3 cells. Cell 7:105-113, 1976 
 6.  Green,H, Kehinde,O: Formation of normally differentiated subcutaneous fat 
pads by an established preadipose cell line. J Cell Physiol 101:169-171, 1979 
 7.  Stephens,JM, Morrison,RF, Pilch,PF: The expression and regulation of 
STATs during 3T3-L1 adipocyte differentiation. J Biol Chem 271:10441-
10444, 1996 
 8.  Bole-Feysot,C, Goffin,V, Edery,M, Binart,N, Kelly,PA: Prolactin (PRL) and 
its receptor: actions, signal transduction pathways and phenotypes observed 
in PRL receptor knockout mice. Endocr Rev 19:225-268, 1998 
 9.  Zeng,R, Aoki,Y, Yoshida,M, Arai,K, Watanabe,S: Stat5B shuttles between 
cytoplasm and nucleus in a cytokine-dependent and -independent manner. J 
Immunol 168:4567-4575, 2002 
 10.  Kisseleva,T, Bhattacharya,S, Braunstein,J, Schindler,CW: Signaling through 
the JAK/STAT pathway, recent advances and future challenges. Gene 285:1-
24, 2002 
 11.  Cella,N, Groner,B, Hynes,NE: Characterization of Stat5a and Stat5b 
homodimers and heterodimers and their association with the glucocortiocoid 
receptor in mammary cells. Mol Cell Biol 18:1783-1792, 1998 
 36
 12.  Kisseleva,T, Bhattacharya,S, Braunstein,J, Schindler,CW: Signaling through 
the JAK/STAT pathway, recent advances and future challenges. Gene 285:1-
24, 2002 
 13.  John,S, Vinkemeier,U, Soldaini,E, Darnell,JE, Jr., Leonard,WJ: The 
significance of tetramerization in promoter recruitment by Stat5. Mol Cell 
Biol 19:1910-1918, 1999 
 14.  Zhu,M, John,S, Berg,M, Leonard,WJ: Functional association of Nmi with 
Stat5 and Stat1 in IL-2- and IFNgamma-mediated signaling. Cell 96:121-130, 
1999 
 15.  Schindler,C, Levy,DE, Decker,T: JAK-STAT signaling: from interferons to 
cytokines. J Biol Chem 282:20059-20063, 2007 
 16.  Darnell,JE, Jr.: STATs and gene regulation. Science 277:1630-1635, 1997 
 17.  Hemmann,U, Gerhartz,C, Heesel,B, Sasse,J, Kurapkat,G, Grotzinger,J, 
Wollmer,A, Zhong,Z, Darnell,JE, Jr., Graeve,L, Heinrich,PC, Horn,F: 
Differential activation of acute phase response factor/Stat3 and Stat1 via the 
cytoplasmic domain of the interleukin 6 signal transducer gp130. II. Src 
homology SH2 domains define the specificity of stat factor activation. J Biol 
Chem 271:12999-13007, 1996 
 18.  Schindler,C, Levy,DE, Decker,T: JAK-STAT signaling: from interferons to 
cytokines. J Biol Chem 282:20059-20063, 2007 
 19.  Nagy,ZS, Wang,Y, Erwin-Cohen,RA, Aradi,J, Monia,B, Wang,LH, 
Stepkowski,SM, Rui,H, Kirken,RA: Interleukin-2 family cytokines stimulate 
phosphorylation of the Pro-Ser-Pro motif of Stat5 transcription factors in 
human T cells: resistance to suppression of multiple serine kinase pathways. 
J Leukoc Biol 72:819-828, 2002 
 20.  Teglund,S, McKay,C, Schuetz,E, van Deursen,JM, Stravopodis,D, Wang,D, 
Brown,M, Bodner,S, Grosveld,G, Ihle,JN: Stat5a and Stat5b proteins have 
essential and nonessential, or redundant, roles in cytokine responses. Cell 
93:841-850, 1998 
 37
 21.  Bole-Feysot,C, Goffin,V, Edery,M, Binart,N, Kelly,PA: Prolactin (PRL) and 
its receptor: actions, signal transduction pathways and phenotypes observed 
in PRL receptor knockout mice. Endocr Rev 19:225-268, 1998 
 22.  Teglund,S, McKay,C, Schuetz,E, van Deursen,JM, Stravopodis,D, Wang,D, 
Brown,M, Bodner,S, Grosveld,G, Ihle,JN: Stat5a and Stat5b proteins have 
essential and nonessential, or redundant, roles in cytokine responses. Cell 
93:841-850, 1998 
 23.  Teglund,S, McKay,C, Schuetz,E, van Deursen,JM, Stravopodis,D, Wang,D, 
Brown,M, Bodner,S, Grosveld,G, Ihle,JN: Stat5a and Stat5b proteins have 
essential and nonessential, or redundant, roles in cytokine responses. Cell 
93:841-850, 1998 
 24.  Gerlo,S, Verdood,P, Hooghe-Peters,EL, Kooijman,R: Modulation of 
prolactin expression in human T lymphocytes by cytokines. J Neuroimmunol 
162:190-193, 2005 
 25.  Gellersen,B, Bonhoff,A, Hunt,N, Bohnet,HG: Decidual-type prolactin 
expression by the human myometrium. Endocrinology 129:158-168, 1991 
 26.  Fielder,PJ, Talamantes,F: The lipolytic effects of mouse placental lactogen II, 
mouse prolactin, and mouse growth hormone on adipose tissue from virgin 
and pregnant mice. Endocrinology 121:493-497, 1987 
 27.  McAveney,KM, Gimble,JM, Yu-Lee,L: Prolactin receptor expression during 
adipocyte differentiation of bone marrow stroma. Endocrinology 137:5723-
5726, 1996 
 28.  Hugo,ER, Brandebourg,TD, Comstock,CE, Gersin,KS, Sussman,JJ, Ben-
Jonathan,N: LS14: a novel human adipocyte cell line that produces 
prolactin. Endocrinology 147:306-313, 2006 
 29.  Gerlo,S, Verdood,P, Hooghe-Peters,EL, Kooijman,R: Modulation of 
prolactin expression in human T lymphocytes by cytokines. J Neuroimmunol 
162:190-193, 2005 
 30.  Gellersen,B, Bonhoff,A, Hunt,N, Bohnet,HG: Decidual-type prolactin 
expression by the human myometrium. Endocrinology 129:158-168, 1991 
 38
 31.  Moller,N, Jorgensen,JO, Moller,J, Orskov,L, Ovesen,P, Schmitz,O, 
Christiansen,JS, Orskov,H: Metabolic effects of growth hormone in humans. 
Metabolism 44:33-36, 1995 
 32.  Magri,KA, Adamo,M, Leroith,D, Etherton,TD: The inhibition of insulin 
action and glucose metabolism by porcine growth hormone in porcine 
adipocytes is not the result of any decrease in insulin binding or insulin 
receptor kinase activity. Biochem J 266:107-113, 1990 
 33.  Veldhuis,JD, Iranmanesh,A, Ho,KK, Waters,MJ, Johnson,ML, 
Lizarralde,G: Dual defects in pulsatile growth hormone secretion and 
clearance subserve the hyposomatotropism of obesity in man. J Clin 
Endocrinol Metab 72:51-59, 1991 
 34.  Kopchick,JJ, Bellush,LL, Coschigano,KT: Transgenic models of growth 
hormone action. Annu Rev Nutr 19:437-461, 1999 
 35.  Biddinger,SB, Kahn,CR: From mice to men: insights into the insulin 
resistance syndromes. Annu Rev Physiol 68:123-158, 2006 
 36.  Moller,N, Jorgensen,JO, Moller,J, Orskov,L, Ovesen,P, Schmitz,O, 
Christiansen,JS, Orskov,H: Metabolic effects of growth hormone in humans. 
Metabolism 44:33-36, 1995 
 37.  Schernthaner,G, Prager,R, Punzengruber,C, Luger,A: Severe 
hyperprolactinaemia is associated with decreased insulin binding in vitro and 
insulin resistance in vivo 
1. Diabetologia 28:138-142, 1985 
 38.  Terauchi,Y, Tsuji,Y, Satoh,S, Minoura,H, Murakami,K, Okuno,A, Inukai,K, 
Asano,T, Kaburagi,Y, Ueki,K, Nakajima,H, Hanafusa,T, Matsuzawa,Y, 
Sekihara,H, Yin,Y, Barrett,JC, Oda,H, Ishikawa,T, Akanuma,Y, Komuro,I, 
Suzuki,M, Yamamura,K, Kodama,T, Suzuki,H, Yamamura,K, Kodama,T, 
Suzuki,H, Koyasu,S, Aizawa,S, Tobe,K, Fukui,Y, Yazaki,Y, Kadowaki,T: 
Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 
alpha subunit of phosphoinositide 3-kinase. Nat Genet 21:230-235, 1999 
 39.  Ueki,K, Algenstaedt,P, Mauvais-Jarvis,F, Kahn,CR: Positive and negative 
regulation of phosphoinositide 3-kinase-dependent signaling pathways by 
three different gene products of the p85alpha regulatory subunit 
1. Mol Cell Biol 20:8035-8046, 2000 
 39
 40.  del Rincon,JP, Iida,K, Gaylinn,BD, McCurdy,CE, Leitner,JW, Barbour,LA, 
Kopchick,JJ, Friedman,JE, Draznin,B, Thorner,MO: Growth hormone 
regulation of p85alpha expression and phosphoinositide 3-kinase activity in 
adipose tissue: mechanism for growth hormone-mediated insulin resistance 
1. Diabetes 56:1638-1646, 2007 
 41.  Greenhalgh,CJ, Hilton,DJ: Negative regulation of cytokine signaling. J 
Leukoc Biol 70:348-356, 2001 
 42.  Greenhalgh,CJ, Hilton,DJ: Negative regulation of cytokine signaling. J 
Leukoc Biol 70:348-356, 2001 
 43.  Greenhalgh,CJ, Hilton,DJ: Negative regulation of cytokine signaling. J 
Leukoc Biol 70:348-356, 2001 
 44.  Rycyzyn,MA, Clevenger,CV: The intranuclear prolactin/cyclophilin B 
complex as a transcriptional inducer. Proc Natl Acad Sci U S A 99:6790-6795, 
2002 
 45.  O'Shea,JJ, Watford,W: A peek at PIAS. Nat Immunol 5:875-876, 2004 
 46.  Dohmen,RJ: SUMO protein modification. Biochim Biophys Acta 1695:113-
131, 2004 
 47.  Hogan,JC, Stephens,JM: The regulation of fatty acid synthase by STAT5A. 
Diabetes 54:1968-1975, 2005 
 48.  Coulter,AA, Stephens,JM: STAT5 activators modulate acyl CoA oxidase 
(AOX) expression in adipocytes and STAT5A binds to the AOX promoter in 
vitro. Biochem Biophys Res Commun 344:1342-1345, 2006 
 49.  White,UA, Coulter,AA, Miles,TK, Stephens,JM: The STAT5A-mediated 
induction of pyruvate dehydrogenase kinase 4 expression by prolactin or 
growth hormone in adipocytes. Diabetes 56:1623-1629, 2007 
 50.  Sugden,MC, Fryer,LG, Orfali,KA, Priestman,DA, Donald,E, Holness,MJ: 
Studies of the long-term regulation of hepatic pyruvate dehydrogenase 
kinase. Biochem J 329 ( Pt 1):89-94, 1998 
 40
 51.  Schmitt-Ney,M, Happ,B, Ball,RK, Groner,B: Developmental and 
environmental regulation of a mammary gland-specific nuclear factor 
essential for transcription of the gene encoding beta-casein. Proc Natl Acad 
Sci U S A 89:3130-3134, 1992 
 52.  Wyszomierski,SL, Rosen,JM: Cooperative effects of STAT5 (signal 
transducer and activator of transcription 5) and C/EBPbeta 
(CCAAT/enhancer-binding protein-beta) on beta-casein gene transcription 
are mediated by the glucocorticoid receptor. Mol Endocrinol 15:228-240, 
2001 
 53.  Meier,VS, Groner,B: The nuclear factor YY1 participates in repression of 
the beta-casein gene promoter in mammary epithelial cells and is 
counteracted by mammary gland factor during lactogenic hormone 
induction. Mol Cell Biol 14:128-137, 1994 
 54.  Martino,A, Holmes,JH, Lord,JD, Moon,JJ, Nelson,BH: Stat5 and Sp1 
regulate transcription of the cyclin D2 gene in response to IL-2. J Immunol 
166:1723-1729, 2001 
 55.  Pfitzner,E, Jahne,R, Wissler,M, Stoecklin,E, Groner,B: p300/CREB-binding 
protein enhances the prolactin-mediated transcriptional induction through 
direct interaction with the transactivation domain of Stat5, but does not 
participate in the Stat5-mediated suppression of the glucocorticoid response. 
Mol Endocrinol 12:1582-1593, 1998 
 56.  Zhu,M, John,S, Berg,M, Leonard,WJ: Functional association of Nmi with 
Stat5 and Stat1 in IL-2- and IFNgamma-mediated signaling. Cell 96:121-130, 
1999 
 57.  Pajvani,UB, Hawkins,M, Combs,TP, Rajala,MW, Doebber,T, Berger,JP, 
Wagner,JA, Wu,M, Knopps,A, Xiang,AH, Utzschneider,KM, Kahn,SE, 
Olefsky,JM, Buchanan,TA, Scherer,PE: Complex distribution, not absolute 
amount of adiponectin, correlates with thiazolidinedione-mediated 
improvement in insulin sensitivity. J Biol Chem 279:12152-12162, 2004 
 58.  Fruebis,J, Tsao,TS, Javorschi,S, Ebbets-Reed,D, Erickson,MR, Yen,FT, 
Bihain,BE, Lodish,HF: Proteolytic cleavage product of 30-kDa adipocyte 
complement-related protein increases fatty acid oxidation in muscle and 
causes weight loss in mice. Proc Natl Acad Sci U S A 98:2005-2010, 2001 
 41
 59.  Mohan,V, Deepa,R, Pradeepa,R, Vimaleswaran,KS, Mohan,A, 
Velmurugan,K, Radha,V: Association of low adiponectin levels with the 
metabolic syndrome--the Chennai Urban Rural Epidemiology Study 
(CURES-4) 
1. Metabolism 54:476-481, 2005 
 60.  Avogaro,A, Giorda,C, Maggini,M, Mannucci,E, Raschetti,R, Lombardo,F, 
Spila-Alegiani,S, Turco,S, Velussi,M, Ferrannini,E: Incidence of coronary 
heart disease in type 2 diabetic men and women: impact of microvascular 
complications, treatment, and geographic location 
1. Diabetes Care 30:1241-1247, 2007 
 61.  Laughlin,GA, Barrett-Connor,E, May,S, Langenberg,C: Association of 
adiponectin with coronary heart disease and mortality: the Rancho Bernardo 
study 
3. Am J Epidemiol 165:164-174, 2007 
 62.  Arita,Y, Kihara,S, Ouchi,N, Takahashi,M, Maeda,K, Miyagawa,J, Hotta,K, 
Shimomura,I, Nakamura,T, Miyaoka,K, Kuriyama,H, Nishida,M, 
Yamashita,S, Okubo,K, Matsubara,K, Muraguchi,M, Ohmoto,Y, 
Funahashi,T, Matsuzawa,Y: Paradoxical decrease of an adipose-specific 
protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79-83, 
1999 
 63.  Nawrocki,AR, Rajala,MW, Tomas,E, Pajvani,UB, Saha,AK, 
Trumbauer,ME, Pang,Z, Chen,AS, Ruderman,NB, Chen,H, Rossetti,L, 
Scherer,PE: Mice lacking adiponectin show decreased hepatic insulin 
sensitivity and reduced responsiveness to peroxisome proliferator-activated 
receptor gamma agonists. J Biol Chem 281:2654-2660, 2006 
 64.  Yamauchi,T, Kadowaki,T: [The molecular mechanisms by which PPAR 
gamma/RXR inhibitors improve insulin resistance]. Nippon Rinsho 59:2245-
2254, 2001 
 65.  Pajvani,UB, Hawkins,M, Combs,TP, Rajala,MW, Doebber,T, Berger,JP, 
Wagner,JA, Wu,M, Knopps,A, Xiang,AH, Utzschneider,KM, Kahn,SE, 
Olefsky,JM, Buchanan,TA, Scherer,PE: Complex distribution, not absolute 
amount of adiponectin, correlates with thiazolidinedione-mediated 
improvement in insulin sensitivity. J Biol Chem 279:12152-12162, 2004 
 42
 66.  Yamauchi,T, Kamon,J, Ito,Y, Tsuchida,A, Yokomizo,T, Kita,S, Sugiyama,T, 
Miyagishi,M, Hara,K, Tsunoda,M, Murakami,K, Ohteki,T, Uchida,S, 
Takekawa,S, Waki,H, Tsuno,NH, Shibata,Y, Terauchi,Y, Froguel,P, Tobe,K, 
Koyasu,S, Taira,K, Kitamura,T, Shimizu,T, Nagai,R, Kadowaki,T: Cloning 
of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 
423:762-769, 2003 
 67.  Kim,JY, van de,WE, Laplante,M, Azzara,A, Trujillo,ME, Hofmann,SM, 
Schraw,T, Durand,JL, Li,H, Li,G, Jelicks,LA, Mehler,MF, Hui,DY, 
Deshaies,Y, Shulman,GI, Schwartz,GJ, Scherer,PE: Obesity-associated 
improvements in metabolic profile through expansion of adipose tissue. J 
Clin Invest 117:2621-2637, 2007 
 68.  Yamauchi,T, Kamon,J, Ito,Y, Tsuchida,A, Yokomizo,T, Kita,S, Sugiyama,T, 
Miyagishi,M, Hara,K, Tsunoda,M, Murakami,K, Ohteki,T, Uchida,S, 
Takekawa,S, Waki,H, Tsuno,NH, Shibata,Y, Terauchi,Y, Froguel,P, Tobe,K, 
Koyasu,S, Taira,K, Kitamura,T, Shimizu,T, Nagai,R, Kadowaki,T: Cloning 
of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 
423:762-769, 2003 
 69.  Yamauchi,T, Kamon,J, Ito,Y, Tsuchida,A, Yokomizo,T, Kita,S, Sugiyama,T, 
Miyagishi,M, Hara,K, Tsunoda,M, Murakami,K, Ohteki,T, Uchida,S, 
Takekawa,S, Waki,H, Tsuno,NH, Shibata,Y, Terauchi,Y, Froguel,P, Tobe,K, 
Koyasu,S, Taira,K, Kitamura,T, Shimizu,T, Nagai,R, Kadowaki,T: Cloning 
of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 
423:762-769, 2003 
 70.  Yamauchi,T, Kamon,J, Ito,Y, Tsuchida,A, Yokomizo,T, Kita,S, Sugiyama,T, 
Miyagishi,M, Hara,K, Tsunoda,M, Murakami,K, Ohteki,T, Uchida,S, 
Takekawa,S, Waki,H, Tsuno,NH, Shibata,Y, Terauchi,Y, Froguel,P, Tobe,K, 
Koyasu,S, Taira,K, Kitamura,T, Shimizu,T, Nagai,R, Kadowaki,T: Cloning 
of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 
423:762-769, 2003 
 71.  Yamauchi,T, Kamon,J, Ito,Y, Tsuchida,A, Yokomizo,T, Kita,S, Sugiyama,T, 
Miyagishi,M, Hara,K, Tsunoda,M, Murakami,K, Ohteki,T, Uchida,S, 
Takekawa,S, Waki,H, Tsuno,NH, Shibata,Y, Terauchi,Y, Froguel,P, Tobe,K, 
Koyasu,S, Taira,K, Kitamura,T, Shimizu,T, Nagai,R, Kadowaki,T: Cloning 
of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 
423:762-769, 2003 
 43
 72.  Bluher,M, Bullen,JW, Jr., Lee,JH, Kralisch,S, Fasshauer,M, Kloting,N, 
Niebauer,J, Schon,MR, Williams,CJ, Mantzoros,CS: Circulating adiponectin 
and expression of adiponectin receptors in human skeletal muscle: 
associations with metabolic parameters and insulin resistance and regulation 
by physical training. J Clin Endocrinol Metab 91:2310-2316, 2006 
 73.  Civitarese,AE, Jenkinson,CP, Richardson,D, Bajaj,M, Cusi,K, Kashyap,S, 
Berria,R, Belfort,R, DeFronzo,RA, Mandarino,LJ, Ravussin,E: Adiponectin 
receptors gene expression and insulin sensitivity in non-diabetic Mexican 
Americans with or without a family history of Type 2 diabetes. Diabetologia 
47:816-820, 2004 
 74.  Mao,X, Kikani,CK, Riojas,RA, Langlais,P, Wang,L, Ramos,FJ, Fang,Q, 
Christ-Roberts,CY, Hong,JY, Kim,RY, Liu,F, Dong,LQ: APPL1 binds to 
adiponectin receptors and mediates adiponectin signalling and function. Nat 
Cell Biol 8:516-523, 2006 
 75.  Miaczynska,M, Christoforidis,S, Giner,A, Shevchenko,A, Uttenweiler-
Joseph,S, Habermann,B, Wilm,M, Parton,RG, Zerial,M: APPL proteins link 
Rab5 to nuclear signal transduction via an endosomal compartment. Cell 
116:445-456, 2004 
 76.  Hardie,DG: The AMP-activated protein kinase pathway--new players 
upstream and downstream. J Cell Sci 117:5479-5487, 2004 
 77.  Yamauchi,T, Kamon,J, Ito,Y, Tsuchida,A, Yokomizo,T, Kita,S, Sugiyama,T, 
Miyagishi,M, Hara,K, Tsunoda,M, Murakami,K, Ohteki,T, Uchida,S, 
Takekawa,S, Waki,H, Tsuno,NH, Shibata,Y, Terauchi,Y, Froguel,P, Tobe,K, 
Koyasu,S, Taira,K, Kitamura,T, Shimizu,T, Nagai,R, Kadowaki,T: Cloning 
of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 
423:762-769, 2003 
 78.  Roux,PP, Blenis,J: ERK and p38 MAPK-activated protein kinases: a family 
of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 
68:320-344, 2004 
 79.  Barger,PM, Browning,AC, Garner,AN, Kelly,DP: p38 mitogen-activated 
protein kinase activates peroxisome proliferator-activated receptor alpha: a 
potential role in the cardiac metabolic stress response. J Biol Chem 
276:44495-44501, 2001 
 44
 80.  van Raalte,DH, Li,M, Pritchard,PH, Wasan,KM: Peroxisome proliferator-
activated receptor (PPAR)-alpha: a pharmacological target with a promising 
future. Pharm Res 21:1531-1538, 2004 
 81.  Wang,C, Mao,X, Wang,L, Liu,M, Wetzel,MD, Guan,KL, Dong,LQ, Liu,F: 
Adiponectin sensitizes insulin signaling by reducing p70 S6 kinase-mediated 
serine phosphorylation of IRS-1. J Biol Chem 282:7991-7996, 2007 
 82.  Kissebah,AH, Sonnenberg,GE, Myklebust,J, Goldstein,M, Broman,K, 
James,RG, Marks,JA, Krakower,GR, Jacob,HJ, Weber,J, Martin,L, 
Blangero,J, Comuzzie,AG: Quantitative trait loci on chromosomes 3 and 17 
influence phenotypes of the metabolic syndrome. Proc Natl Acad Sci U S A 
97:14478-14483, 2000 
 83.  Mori,Y, Otabe,S, Dina,C, Yasuda,K, Populaire,C, Lecoeur,C, Vatin,V, 
Durand,E, Hara,K, Okada,T, Tobe,K, Boutin,P, Kadowaki,T, Froguel,P: 
Genome-wide search for type 2 diabetes in Japanese affected sib-pairs 
confirms susceptibility genes on 3q, 15q, and 20q and identifies two new 
candidate Loci on 7p and 11p. Diabetes 51:1247-1255, 2002 
 84.  Vasseur,F, Helbecque,N, Dina,C, Lobbens,S, Delannoy,V, Gaget,S, Boutin,P, 
Vaxillaire,M, Lepretre,F, Dupont,S, Hara,K, Clement,K, Bihain,B, 
Kadowaki,T, Froguel,P: Single-nucleotide polymorphism haplotypes in the 
both proximal promoter and exon 3 of the APM1 gene modulate adipocyte-
secreted adiponectin hormone levels and contribute to the genetic risk for 
type 2 diabetes in French Caucasians. Hum Mol Genet 11:2607-2614, 2002 
 85.  Hara,K, Boutin,P, Mori,Y, Tobe,K, Dina,C, Yasuda,K, Yamauchi,T, 
Otabe,S, Okada,T, Eto,K, Kadowaki,H, Hagura,R, Akanuma,Y, Yazaki,Y, 
Nagai,R, Taniyama,M, Matsubara,K, Yoda,M, Nakano,Y, Tomita,M, 
Kimura,S, Ito,C, Froguel,P, Kadowaki,T: Genetic variation in the gene 
encoding adiponectin is associated with an increased risk of type 2 diabetes 
in the Japanese population. Diabetes 51:536-540, 2002 
 86.  Vasseur,F, Helbecque,N, Dina,C, Lobbens,S, Delannoy,V, Gaget,S, Boutin,P, 
Vaxillaire,M, Lepretre,F, Dupont,S, Hara,K, Clement,K, Bihain,B, 
Kadowaki,T, Froguel,P: Single-nucleotide polymorphism haplotypes in the 
both proximal promoter and exon 3 of the APM1 gene modulate adipocyte-
secreted adiponectin hormone levels and contribute to the genetic risk for 
type 2 diabetes in French Caucasians. Hum Mol Genet 11:2607-2614, 2002 
 45
 87.  Zacharova,J, Chiasson,JL, Laakso,M: The common polymorphisms (single 
nucleotide polymorphism [SNP] +45 and SNP +276) of the adiponectin gene 
predict the conversion from impaired glucose tolerance to type 2 diabetes: 
the STOP-NIDDM trial. Diabetes 54:893-899, 2005 
 88.  Ohashi,K, Ouchi,N, Kihara,S, Funahashi,T, Nakamura,T, Sumitsuji,S, 
Kawamoto,T, Matsumoto,S, Nagaretani,H, Kumada,M, Okamoto,Y, 
Nishizawa,H, Kishida,K, Maeda,N, Hiraoka,H, Iwashima,Y, Ishikawa,K, 
Ohishi,M, Katsuya,T, Rakugi,H, Ogihara,T, Matsuzawa,Y: Adiponectin 
I164T mutation is associated with the metabolic syndrome and coronary 
artery disease. J Am Coll Cardiol 43:1195-1200, 2004 
 89.  Kita,A, Yamasaki,H, Kuwahara,H, Moriuchi,A, Fukushima,K, 
Kobayashi,M, Fukushima,T, Takahashi,R, Abiru,N, Uotani,S, Kawasaki,E, 
Eguchi,K: Identification of the promoter region required for human 
adiponectin gene transcription: Association with CCAAT/enhancer binding 
protein-beta and tumor necrosis factor-alpha. Biochem Biophys Res Commun 
331:484-490, 2005 
 90.  Kita,A, Yamasaki,H, Kuwahara,H, Moriuchi,A, Fukushima,K, 
Kobayashi,M, Fukushima,T, Takahashi,R, Abiru,N, Uotani,S, Kawasaki,E, 
Eguchi,K: Identification of the promoter region required for human 
adiponectin gene transcription: Association with CCAAT/enhancer binding 
protein-beta and tumor necrosis factor-alpha. Biochem Biophys Res Commun 
331:484-490, 2005 
 91.  Qiao,L, Maclean,PS, Schaack,J, Orlicky,DJ, Darimont,C, Pagliassotti,M, 
Friedman,JE, Shao,J: C/EBPalpha regulates human adiponectin gene 
transcription through an intronic enhancer. Diabetes 54:1744-1754, 2005 
 92.  Iwaki,M, Matsuda,M, Maeda,N, Funahashi,T, Matsuzawa,Y, Makishima,M, 
Shimomura,I: Induction of adiponectin, a fat-derived antidiabetic and 
antiatherogenic factor, by nuclear receptors. Diabetes 52:1655-1663, 2003 
 93.  Iwaki,M, Matsuda,M, Maeda,N, Funahashi,T, Matsuzawa,Y, Makishima,M, 
Shimomura,I: Induction of adiponectin, a fat-derived antidiabetic and 




 94.  Brunet,A, Bonni,A, Zigmond,MJ, Lin,MZ, Juo,P, Hu,LS, Anderson,MJ, 
Arden,KC, Blenis,J, Greenberg,ME: Akt promotes cell survival by 
phosphorylating and inhibiting a Forkhead transcription factor. Cell 96:857-
868, 1999 
 95.  Qiao,L, Shao,J: SIRT1 regulates adiponectin gene expression through Foxo1-
C/enhancer-binding protein alpha transcriptional complex. J Biol Chem 
281:39915-39924, 2006 
 96.  van der Heide,LP, Smidt,MP: Regulation of FoxO activity by CBP/p300-
mediated acetylation. Trends Biochem Sci 30:81-86, 2005 
 97.  Park,SK, Oh,SY, Lee,MY, Yoon,S, Kim,KS, Kim,JW: CCAAT/enhancer 
binding protein and nuclear factor-Y regulate adiponectin gene expression in 
adipose tissue. Diabetes 53:2757-2766, 2004 
 98.  del Castillo-Olivares,A, Gil,G: Alpha 1-fetoprotein transcription factor is 
required for the expression of sterol 12alpha -hydroxylase, the specific 
enzyme for cholic acid synthesis. Potential role in the bile acid-mediated 
regulation of gene transcription 
1. J Biol Chem 275:17793-17799, 2000 
 99.  Tontonoz,P, Hu,E, Graves,RA, Budavari,AI, Spiegelman,BM: mPPAR 
gamma 2: tissue-specific regulator of an adipocyte enhancer 
1. Genes Dev 8:1224-1234, 1994 
 100.  Laemmli,UK: Cleavage of structural proteins during the assembly of the 
head of bacteriophage T4. Nature 227:680-685, 1970 
 101.  Ritzenthaler,JD, Goldstein,RH, Fine,A, Lichtler,A, Rowe,DW, Smith,BD: 
Transforming-growth-factor-beta activation elements in the distal promoter 
regions of the rat alpha 1 type I collagen gene. Biochem J 280 ( Pt 1):157-162, 
1991 
 102.  Nilsson,L, Binart,N, Bohlooly,Y, Bramnert,M, Egecioglu,E, Kindblom,J, 
Kelly,PA, Kopchick,JJ, Ormandy,CJ, Ling,C, Billig,H: Prolactin and growth 
hormone regulate adiponectin secretion and receptor expression in adipose 
tissue. Biochem Biophys Res Commun 331:1120-1126, 2005 
 47
 103.  Lecine,P, Algarte,M, Rameil,P, Beadling,C, Bucher,P, Nabholz,M, Imbert,J: 
Elf-1 and Stat5 bind to a critical element in a new enhancer of the human 
interleukin-2 receptor alpha gene 
1. Mol Cell Biol 16:6829-6840, 1996 
 104.  John,S, Vinkemeier,U, Soldaini,E, Darnell,JE, Jr., Leonard,WJ: The 
significance of tetramerization in promoter recruitment by Stat5. Mol Cell 
Biol 19:1910-1918, 1999 
 105.  Soldaini,E, John,S, Moro,S, Bollenbacher,J, Schindler,U, Leonard,WJ: DNA 
binding site selection of dimeric and tetrameric Stat5 proteins reveals a large 
repertoire of divergent tetrameric Stat5a binding sites. Mol Cell Biol 20:389-
401, 2000 
 106.  Xu,X, Sun,YL, Hoey,T: Cooperative DNA binding and sequence-selective 
recognition conferred by the STAT amino-terminal domain. Science 273:794-
797, 1996 
 107.  Ascherman,DP, Migone,TS, Friedmann,MC, Leonard,WJ: Interleukin-2 (IL-
2)-mediated induction of the IL-2 receptor alpha chain gene. Critical role of 
two functionally redundant tyrosine residues in the IL-2 receptor beta chain 
cytoplasmic domain and suggestion that these residues mediate more than 
Stat5 activation 
1. J Biol Chem 272:8704-8709, 1997 
 108.  Veldhuis,JD, Johnson,ML: Operating characteristics of the hypothalamo-
pituitary-gonadal axis in men: circadian, ultradian, and pulsatile release of 
prolactin and its temporal coupling with luteinizing hormone 
2. J Clin Endocrinol Metab 67:116-123, 1988 
 109.  Pijl,H: Reduced dopaminergic tone in hypothalamic neural circuits: 
expression of a "thrifty" genotype underlying the metabolic syndrome? Eur 
J Pharmacol 480:125-131, 2003 
 110.  Kok,P, Roelfsema,F, Frolich,M, Meinders,AE, Pijl,H: Prolactin release is 
enhanced in proportion to excess visceral fat in obese women 
1. J Clin Endocrinol Metab 89:4445-4449, 2004 
  
 48
111. Hara,K, Boutin,P, Mori,Y, Tobe,K, Dina,C, Yasuda,K, Yamauchi,T, Otabe,S, 
Okada,T, Eto,K, Kadowaki,H, Hagura,R, Akanuma,Y, Yazaki,Y, Nagai,R, 
Taniyama,M, Matsubara,K, Yoda,M, Nakano,Y, Tomita,M, Kimura,S, 
Ito,C, Froguel,P, Kadowaki,T: Genetic variation in the gene encoding 
adiponectin is associated with an increased risk of type 2 diabetes in the 
Japanese population. Diabetes 51:536-540, 2002 
 112.  Lurbe,E, Torro,I, Aguilar,F, Alvarez,J, Alcon,J, Pascual,JM, Redon,J: 
Added impact of obesity and insulin resistance in nocturnal blood pressure 
elevation in children and adolescents 






















  Joel Elisha Maier was born in August 1983, in Covington Louisiana. He graduated 
from Covington High School in 2001. After graduation, he attended Louisiana State 
University where he earned a Bachelor of Science degree in biochemistry in 2005, and 
continued there afterward to begin his graduate career.  
 
 
